thrive pharmacy semaglutide and tirzepatide are both injectable medications used in medical weight management—but they act on different metabolic pathways, which is why patient selection matters. Semaglutide (GLP-1 receptor agonist): • Primarily targets appetite Semaglutide is a FDA-approved GLP-1

B12 injections do not require any type of aftercare, as they are very safe and cause little discomfort beyond the initial sting of the needle in the thigh

No anaesthetic is needed for this treatment

A 2023 case series in the Journal of the American Pharmacists Association documented three patients who made 10-fold dosing errors with compounded vials because the syringes, vials, and unit markings (mg vs mL vs units) were easy to misread

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients Weekly treatments of semaglutide, a GLP-1 receptor agonist from Novo Nordisk originally developed to treat diabetes, are associated with reducing a patients major adverse cardiovascular event (MACE) risk by 20%, according to initial results from the SELECT trial